Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof

A compound of formula I:

• wherein Z is H, CO2H, NH2, SH and OH;
• wherein m is 2 to 16;
• wherein R1 is the same or different moiety and is a compound of formula VII:
• L is a linker, wherein the linker is a C8 to C20 alkyl, alkylamino, alkenyl, alkynyl, hydroxyalkyl, alkoxy, dialkylamino thioalkyl, thioalkenyl, thioalkynyl, aryloxy, acyloxy, thioacyl, amido, polyethylene glycol and sulphonamido, wherein each of alkyl or aryl moiety may be unsubstituted or substituted with one or more substituents selected from the group consisting of halo, hydroxy, carboxy, phosphoryl, phosphonyl, phosphono C1-C6 alkyl, carboxy C1-C6 alkyl, dicarboxy C1-C6 alkyl, dicarboxy halo C1-C6 alkyl, sulfonyl, cyano, nitro, alkoxy, alkylthio, acyl, acyloxy, thioacyl, acylthio, aryloxy, amino, alkylamino, dialkylamino, trialkylamino, arylalkylamino, guanidino, aldehydo, ureido, and aminocarbonyl;
• and
• alternatively, R1 is a peptide ligand to an enzyme or endothelial receptor, and wherein R2 is a chelating moiety, a fluorescent dye or H,
• wherein when R2 is a chelating moiety, it can be bound to a metal ion useful in imaging, or as a cytotoxic moiety;
• or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.